Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study

Background Common intravenous recombinant tissue plasminogen activator (IV rt-PA) exclusion criteria may substantially limit the use of thrombolysis. Preliminary data have shown that the SMART (Simplified Management of Acute stroke using Revised Treatment) criteria greatly expand patient eligibility...

Full description

Saved in:
Bibliographic Details
Published inJournal of stroke and cerebrovascular diseases Vol. 25; no. 5; pp. 1110 - 1118
Main Authors Sørensen, Sigrid B., MD, Barazangi, Nobl, MD, PhD, Chen, Charlene, MD, Wong, Christine, MD, Grosvenor, David, MPH, Rose, Jack, MD, Bedenk, Ann, RN, Morrow, Megan, RN, McDermott, Dan, MD, Hove, Jens D., MD, PhD, Tong, David C., MD, FAAN, FAHA, FANA
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.05.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Background Common intravenous recombinant tissue plasminogen activator (IV rt-PA) exclusion criteria may substantially limit the use of thrombolysis. Preliminary data have shown that the SMART (Simplified Management of Acute stroke using Revised Treatment) criteria greatly expand patient eligibility by reducing thrombolysis exclusions, but they have not been assessed on a large scale. We evaluated the safety and efficacy of general adoption of SMART thrombolysis criteria to a large regional stroke network. Methods Retrospective analysis of consecutive patients who received IV thrombolysis within a regional stroke network was performed. Patients were divided into those receiving thrombolysis locally versus at an outside hospital. The primary outcome was modified Rankin Scale score (≤1) at discharge and the main safety outcome was symptomatic intracranial hemorrhage (sICH) rate. Results There were 539 consecutive patients, and 50.5% received thrombolysis at an outside facility. Ninety percent of the patients possessed common conventional IV rt-PA contraindications. There were no significant differences between local and network treated patients in favorable outcome (45.4% versus 37.4%; odds ratio [OR], .72; P  > .09), mortality (9% versus 14%; OR, 1.6; P  > .07), or sICH rate (2.6% versus 5.1%; OR, 2.0; P  = .13). Multivariate analysis showed no association between receiving IV rt-PA at an outlying spoke hospital and higher rate of sICH or worse outcome at discharge. Conclusions Generalized application of SMART criteria is safe and effective. Widespread application of these criteria could substantially increase the proportion of patients who might qualify for treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1052-3057
1532-8511
DOI:10.1016/j.jstrokecerebrovasdis.2016.01.016